Supplementary Table 4. Baseline characteristics of patients in the expanded cohort with at least three glucose measurements

Characteristics	Total (n=361)	Normoglycemic (Group 1, n=115)	Persistently elevated stable (Group 2, n=178)	Variable hyperglycemic (Group 3, n=68)	*P*
Age (yr)	73.7±12.1	71.7±12.9	74.9±11.4	73.7±12.2	0.081
Male sex	196 (54.3)	63 (54.8)	99 (55.6)	34 (50.0)	0.725
Medical history*					
Hypertension	259 (72.8)	68 (61.3)	140 (79.1)	51 (75.0)	0.004
Diabetes	130 (36.5)	9 (8.1)	86 (48.6)	35 (51.5)	<0.001
Dyslipidemia	138 (38.8)	40 (36.0)	66 (37.3)	32 (47.1)	0.289
Coronary artery disease	60 (16.9)	17 (15.3)	30 (16.9)	13 (19.1)	0.804
Atrial fibrillation	191 (53.7)	60 (54.1)	98 (55.4)	33 (48.5)	0.627
Current smoking	44 (12.4)	15 (13.5)	20 (11.3)	9 (13.2)	0.832
Current alcohol consumption	79 (22.2)	27 (24.3)	42 (23.7)	10 (14.7)	0.254
Family history of ischemic stroke	54 (15.2)	21 (18.9)	21 (11.9)	12 (17.6)	0.219
mRS at one day prior to the ischemic stroke onset					0.980
0	277 (76.7)	89 (77.4)	136 (76.4)	52 (76.5)	
1	84 (23.3)	26 (22.6)	42 (23.6)	16 (23.5)	
Initial NIHSS score	13 (10–18)	13 (10–18)	13 (10–18)	13 (9–17)	0.343
ASPECTS	8 (6–9)	8 (6–9)	8 (6–9)	8 (6–9)	0.360
Occlusion site					
Intracranial ICA	93 (25.8)	24 (20.9)	47 (26.4)	22 (32.4)	0.221
MCA M1	213 (59.0)	72 (62.6)	96 (53.9)	45 (66.2)	0.138
M1-equivalent M2	91 (25.2)	29 (25.2)	50 (28.1)	12 (17.6)	0.241
TOAST classification					0.580
CE	221 (61.2)	73 (63.5)	110 (61.8)	38 (55.9)	
Non-CE	140 (38.8)	42 (36.5)	68 (38.2)	30 (44.1)	
Intravenous thrombolysis	175 (48.5)	55 (47.8)	95 (53.4)	25 (36.8)	0.065
eTICI grade*					0.627
0	14 (3.9)	4 (3.5)	7 (4.0)	3 (4.5)	
1	10 (2.8)	1 (0.9)	7 (4.0)	2 (3.0)	
2a	28 (7.9)	6 (5.2)	17 (9.7)	5 (7.6)	
2b	149 (41.9)	52 (45.2)	72 (41.1)	25 (37.9)	
2c	76 (21.3)	21 (18.3)	39 (22.3)	16 (24.2)	
3	79 (22.2)	31 (27.0)	33 (18.9)	15 (22.7)	
Time from onset to ED arrival (min)	92 (46–203)	79 (41–204)	92 (50–169)	143 (53–247)	0.123
Time from arrival to thrombectomy (min)	104 (79–138)	103 (77–150)	107 (82–132)	98 (77–131)	0.614
Time from arrival to intravenous alteplase (min)	40 (28–57)	34 (27–52)	44 (29–58)	38 (20–57)	0.205
HbA1c (%)	6.2±1.2	5.6±0.4	6.4±1.1	6.5±1.8	<0.001

Values are presented as mean±standard deviation, n (%), or median (interquartile range).
mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; ASPECTS, Alberta Stroke Program Early Computed Tomography Score; ICA, internal carotid artery; MCA, middle cerebral artery; TOAST, Trial of Org 10172 in Acute Stroke Treatment; CE, cardioembolism; eTICI, extended thrombolysis in cerebral infarction; ED, emergency department; HbA1c, hemoglobin A1c.
*Medical history and eTICI grade were unavailable in 5 patients; percentages are based on patients with available data.